Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xiaowu Xu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5101349004. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 0, last author 1)
Trials
4
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper, 2 trials · 2020: 1 paper · 2021: 1 trial · 2022: 1 paper · 2023: 1 paper, 1 trial · 2024: 2 papers · 2025: 2 papers

Papers 10

  1. A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2025.102364↗
  2. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  3. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41401-023-01199-z↗
  4. Laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic ductal adenocarcinoma: protocol of a mul… Co-author DOI 10.21203/rs.3.rs-3993645/v1↗
  5. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
  6. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Co-author DOI 10.3389/fonc.2022.822039↗
  7. Comments: The Prognostic Index Independently Predicts Survival in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Resection. Last author DOI 10.1245/s10434-020-08369-x↗
  8. ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute. Co-author DOI 10.1097/mpa.0000000000001408↗
  9. LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution. Co-author DOI 10.1186/s12876-015-0411-2↗
  10. Cruciferous vegetable consumption and the risk of pancreatic cancer: a meta-analysis. Co-author DOI 10.1186/s12957-015-0454-4↗

Trials 4

  1. LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer Study director NCT05939063↗
  2. Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC Study director NCT04855331↗
  3. Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction Study director NCT06024343↗
  4. Pancreatic Fistula After Minimally Invasive Enucleation Study director NCT06557408↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 7 shared papers, 4 shared trials, 2019–2025 · strength 2.72
  2. Shunrong Ji · 6 shared papers, 2019–2025 · strength 0.92
  3. Wenyan Xu · 4 shared papers, 2019–2025 · strength 0.60
  4. Si Shi · 2 shared papers, 2025 · strength 0.38
  5. Chenjie Zhou · 2 shared papers, 2024 · strength 0.38
  6. Ye Zeng · 2 shared papers, 2022–2024 · strength 0.34
  7. Heli Gao · 2 shared papers, 2022–2024 · strength 0.33
  8. Qifeng Zhuo · 2 shared papers, 2022–2024 · strength 0.33
  9. Wensheng Liu · 2 shared papers, 2022–2024 · strength 0.33
  10. Chen Liu · 2 shared papers, 2023–2025 · strength 0.31
  11. Rong Liu · 2 shared papers, 2023–2025 · strength 0.31
  12. Renyi Qin · 2 shared papers, 2023–2025 · strength 0.31
  13. Yi Qin · 2 shared papers, 2019–2024 · strength 0.28
  14. Qiqing Sun · 2 shared papers, 2019–2020 · strength 0.28
  15. Zheng Li · 2 shared papers, 2022–2023 · strength 0.27
  16. Miaoyan Wei · 1 shared paper, 2025 · strength 0.20
  17. Wei Wang · 1 shared paper, 2025 · strength 0.20
  18. Yifan Zhai · 1 shared paper, 2025 · strength 0.20
  19. Chen Liu · 1 shared paper, 2025 · strength 0.20
  20. Jin Xu · 1 shared paper, 2025 · strength 0.20
  21. Hai-di Chen · 1 shared paper, 2024 · strength 0.20
  22. Haifeng Hu · 1 shared paper, 2024 · strength 0.20
  23. Zheng Li · 1 shared paper, 2024 · strength 0.20
  24. Yiyin Zhang · 1 shared paper, 2020 · strength 0.19
  25. Bing Peng · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.